Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
NEW YORK, Feb. 06, 2017 -- Safirstein Metcalf LLP announces that a class action lawsuit has been filed on behalf of investors who purchased TG Therapeutics, Inc. (“TG Therapeutics” or the “Company”) (NASDAQ:TGTX) securities between September 15, 2014 and October 12, 2016, inclusive (the “Class Period”).
If you purchased TG Therapeutics securities during the class period, and would like more information about getting involved in the TG Therapeutics Shareholder Class Action, please contact Safirstein Metcalf LLP at 1-800-221-0015, or email [email protected].
If you wish to serve as lead plaintiff, you must move the Court no later than March 7, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
TG Therapeutics Shareholder Class Action
TICKER: TGTX
Common Stock CUSIP: 88322Q108
Class Period: September 15, 2014 – October 12, 2016
Lead Plaintiff Date: March 7, 2017
TG Therapeutics is a biopharmaceutical company that focuses on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
According to the Complaint, defendants made false and/or misleading statements regarding the enrollment practices for the Company’s GENUINE Phase 3 trial. TG Therapeutics allegedly failed to disclose to investors that it failed to implement a proper screening protocol in the trial enrolling sites, that the Company was not enrolling patients at the required rate for the study to be completed on time, and that it would never get 330 enrolled patients in the study.
About Safirstein Metcalf LLP
Safirstein Metcalf LLP focuses its practice on shareholder rights. The law firm also practices in the areas of antitrust and consumer protection. All of the Firm’s legal endeavors are rooted in its core mission: provide investor and consumer protection.
Attorney advertising. Prior results do not guarantee a similar outcome.
Safirstein Metcalf LLP Peter Safirstein, Esq. 1250 Broadway 27th Floor New York, NY 10001 1-800-221-0015
